Allogene Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Filed November 29, 2022 under Item 8.01, “Other Events.” The filing reports clinical and research updates presented at Allogene’s R&D Showcase. Allogene is developing allogeneic CAR T-cell therapies for hematologic malignancies and solid tumors, including programs conducted with Servier and using Cellectis technologies.
This is not a periodic financial filing. The filing does not provide revenue, earnings, cash flow, margin, debt, liquidity, or other financial statement metrics.
Clinical and Operating Highlights
| Program | Reported results | Key safety or development update |
|---|---|---|
| ALLO-501/ALLO-501A, ALPHA trials, r/r LBCL | Among 12 patients receiving the preferred Single Dose FCA90 regimen, ORR was 67% and CR rate was 58%. Four of eight patients eligible for six-month follow-up remained in CR at both six and 12 months. Across 48 Alloy-process LBCL patients, ORR was 48% and CR rate was 29%. | No dose-limiting toxicities or GvHD were observed. In the Single Dose FCA90 cohort, one patient had a Grade 3+ infection and two had prolonged Grade 3+ cytopenia. One previously reported Grade 5 event occurred; no new Grade 5 events were reported. |
| ALLO-501A, Phase 2 ALPHA2 | Approximately 100 patients are planned, using a single 120 million CAR+ cell dose and FCA90 lymphodepletion. Primary endpoint is ORR; key secondary endpoint is duration of response. | The trial is described as the first potentially pivotal Phase 2 allogeneic CAR T trial initiated by the company. |
| ALLO-715, UNIVERSAL, r/r MM | At a median follow-up of 14.8 months, ORR was 67% in the FCA60 cohort, VGPR+ rate was 42%, and median duration of response was 9.2 months. All VGPR+ responses were MRD-negative. | In the expansion cohorts, 29% experienced Grade 3+ infections and 29% prolonged Grade 3+ cytopenia. One previously reported Grade 5 event occurred; no new Grade 5 events were reported. |
| ALLO-605, IGNITE, r/r MM | The filing provides no new efficacy results. | Patient enrollment was paused while the company reviews the manufacturing process. |
| ALLO-316, TRAVERSE, advanced/metastatic RCC | Among nine patients with CD70-positive tumors, DCR was 100% and three patients achieved partial responses, including two confirmed responses. Across all 17 patients, ORR was 18% and DCR was 82%. | No GvHD or Grade 5 events were reported. One dose-limiting liver enzyme elevation occurred; 18% had prolonged Grade 3+ cytopenia and one patient had Grade 3 CRS. |
Material Changes and Outlook
- The company concluded that a single-dose FCA90 regimen was preferable to the consolidation regimen in the ALPHA program and is using it in the Phase 2 ALPHA2 trial.
- The Alloy manufacturing process was reported to have performed robustly in the Phase 1 program and is being used in the ongoing Phase 2 ALPHA2 trial.
- Allogene plans a potentially pivotal Phase 2 trial for ALLO-715, subject to regulatory discussions, manufacturing optimization, and transition to its Cell Forge 1 facility.
- TRAVERSE is deploying an investigational CD70 companion diagnostic to identify patients most likely to benefit and will continue evaluating cell doses and lymphodepletion regimens.
- The company plans to advance Dagger technology, intended to reduce host immune-cell rejection of AlloCAR T cells, into next-generation products.
Risks, Contingencies, and Unusual Items
- The reported clinical data are preliminary, based on limited patient populations, and may change following additional follow-up, audit, or verification.
- Phase 1 results may not be predictive of Phase 2 or later-stage outcomes, including the results of ALPHA2.
- Manufacturing processes may affect clinical outcomes, and Allogene may not achieve consistent or reproducible product characteristics, particularly for ALLO-715 and ALLO-605.
- Clinical development depends on patient enrollment, regulatory discussions, trial execution, and successful manufacturing scale-up.
- The filing contains forward-looking statements regarding trial advancement, regulatory progress, manufacturing, product benefits, and potential approvals. No assurance is provided that these objectives will be achieved.
Facts Investors Should Verify
- Updated response durability, survival, and safety results as ALPHA2 and other trials mature.
- Whether Phase 2 ALPHA2 reproduces the preliminary ALPHA results in a larger, single-regimen population.
- Regulatory feedback and the design, timing, and initiation of the planned Phase 2 ALLO-715 trial.
- Resolution of manufacturing issues for ALLO-605 and ALLO-715, including the transition to Cell Forge 1.
- Confirmation of TRAVERSE results in CD70-positive patients using the investigational companion diagnostic.
- The company’s current cash runway, financing needs, debt, and operating expenses, which are not disclosed in this Form 8-K and should be reviewed in the latest periodic filing.